Article
Oncology
Lakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, Reid D. Landes, Mathew Kottarathara, Yetunde Ogunsesan, Shadiqul Hoque, Angel A. Mitma, Clyde Bailey, Kerri M. Hill, Sharmilan Thanendrarajan, Monica Graziutti, Meera Mohan, Maurizio Zangari, Frits van Rhee, Guido Tricot, Carolina Schinke
Summary: Multiple Myeloma (MM) is a common cancer of the bone marrow that remains incurable despite advancements in therapy. While Daratumumab has improved survival rates, heavily pretreated patients who progress on this treatment have poor clinical outcomes. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be a viable treatment option for selected patients who are refractory to Daratumumab.
Article
Immunology
Ane Orrantia, Inigo Terren, Gabirel Astarloa-Pando, Carmen Gonzalez, Alasne Uranga, Juan J. Mateos-Mazon, Juan C. Garcia-Ruiz, Marta Rinon, Mercedes Rey, Silvia Perez-Fernandez, Olatz Zenarruzabeitia, Francisco Borrego
Summary: AutoHSCT in MM patients leads to significant changes in NK cell subsets and phenotype, with patients showing lower frequencies of the mature NKG2A-CD57+ NK cell subset experiencing better clinical outcomes. This suggests that the degree of NK cell maturation post-autoHSCT affects the disease progression and treatment outcomes in MM patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, Natalia Becker, Christina Habermehl, Thomas Hielscher, Marc-Steffen Raab, Jens Hillengass, Sandra Sauer, Carsten Mueller-Tidow, Steffen Luntz, Anna Jauch, Dirk Hose, Anja Seckinger, Peter Brossart, Martin Goerner, Stefan Klein, Martin Schmidt-Hieber, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Hans Martin, Hans W. Lindemann, Christoph Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel
Summary: The efficacy of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) has not been clearly defined in the era of continuous novel agent treatment, however, patients who received this treatment may have benefited.
Article
Oncology
Nina Rosa Neuendorff, Boryana Boshikova, Lutz Frankenstein, Marietta Kirchner, Christian Rohde, Hartmut Goldschmidt, Norbert Frey, Carsten Mueller-Tidow, Karin Jordan, Sandra Sauer, Maike Janssen
Summary: This study assessed the risk of bleeding with antiplatelet therapy (APT) during chemotherapy-induced thrombocytopenia in multiple myeloma patients. The results showed a slightly higher risk of bleeding in the ASA group, but it can still be considered safe to continue ASA during thrombocytopenia with a platelet count of 20-50/nl.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Marc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, Sandra Sauer, Iris Breitkreutz, Karin Jordan, Carsten Mueller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Jens Hillengass, Nicola Giesen
Summary: Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) following re-induction treatment with carfilzomib/lenalidomide/dexamethasone (KRd) led to deep remissions and prolonged progression-free survival (PFS) in patients with relapsed and/or refractory multiple myeloma (RRMM). Maintenance treatment post salvage HDCT/ASCT further enhanced PFS, making this a safe and effective strategy for RRMM patients.
Article
Oncology
Matthew Ho, Saurabh Zanwar, Prashant Kapoor, Morie Gertz, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, David Dingli, Francis Baudi, Eli Muchtar, Nelson Leung, Taxiarchis Kourelis, Rahma Warsame, Amie Fonder, Lisa Hwa, Miriam Hobbs, Robert Kyle, S. Vincent Rajkumar, Shaji Kumar
Summary: This study suggests that MM patients receiving >= 3 years of lenalidomide maintenance post-ASCT have superior outcomes. Lenalidomide refractoriness at first relapse is associated with inferior survival. At first relapse post-maintenance, daratumumab-based regimens show better survival outcomes.
BLOOD CANCER JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
Josefine Ruder, Gianna Dinner, Aleksandra Maceski, Ernesto Berenjeno-Correa, Antonia Maria Mueller, Ilijas Jelcic, Jens Kuhle, Roland Martin
Summary: Autologous hematopoietic stem cell transplantation (aHSCT) is an effective treatment for multiple sclerosis (MS), which normalizes pathological processes and enhances beneficial processes. Biomarker analysis of MS patients undergoing aHSCT showed that serum levels of CXCL10, NfL, and GFAP significantly increased one month after transplantation, but returned to normal after one to two years. Levels of GFAP in cerebrospinal fluid (CSF) increased 24 months after aHSCT, indicating sustained astroglia activation. Other CSF markers remained relatively stable.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Letter
Hematology
Ankit Kansagra, Angela Dispenzieri, Raphael Fraser, Noel Estrada-Merly, Surbhi Sidana, Taiga Nishihori, Doris K. Hansen, Larry D. Anderson, Rahul Banerjee, Naresh Bumma, Binod Dhakal, Jack Khouri, Heather Landau, Cindy Lee, Hira Mian, Sunita Nathan, Bipin Savani, Shaji Kumar, Muzaffar Qazilbash, Nina Shah, Anita D'Souza
Summary: POEMS syndrome, a paraneoplastic syndrome associated with a plasma cell neoplasm, requires effective treatment to control the underlying plasma cell clone. This study reports the outcomes of autoHCT in an international cohort of POEMS syndrome patients, emphasizing toxicities in comparison with multiple myeloma and long-term safety and outcomes.
Article
Clinical Neurology
Peter Alping, Joachim Burman, Jan Lycke, Thomas Frisell, Fredrik Piehl
Summary: This study compares the safety outcomes of different induction therapies for multiple sclerosis patients. It found a higher incidence of thyroid disease in patients treated with alemtuzumab and AHSCT, with a higher incidence of infection in AHSCT-treated patients compared to both alemtuzumab and noninduction therapies. The incidence of nonthyroid autoimmune disease was low for both therapies.
Article
Hematology
Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, Marcos de Lima, Shahrukh Hashmi, Mohamed A. Kharfan-Dabaja, Navneet S. Majhail, Rahul Banerjee, Ayman Saad, Gerhard C. Hildebrandt, Hira Mian, Muhammad Bilal Abid, Minoo Battiwalla, Lazaros J. Lekakis, Sagar S. Patel, Hemant S. Murthy, Yago Nieto, Christopher Strouse, Sherif M. Badawy, Samer Al Hadidi, Bhagirathbhai Dholaria, Mahmoud Aljurf, David H. Vesole, Cindy H. Lee, Attaphol Pawarode, Usama Gergis, Kevin C. Miller, Leona A. Holmberg, Aimaz Afrough, Melhem Solh, Pashna N. Munshi, Taiga Nishihori, Larry D. Anderson Jr, Baldeep Wirk, Gurbakhash Kaur, Muzaffar H. Qazilbash, Nina Shah, Shaji K. Kumar, Saad Z. Usmani
Summary: The use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT), has significantly improved the overall survival (OS) in multiple myeloma (MM) patients. However, the use of lenalidomide maintenance after auto-HSCT has been associated with an increased risk of second primary malignancies (SPM) and second hematological malignancies (SHM). This study evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in MM patients after auto-HSCT using registry data.
Article
Oncology
Pashna N. Munshi, David H. Vesole, Andrew St Martin, Omar Davila, Shaji Kumar, Muzaffar Qazilbash, Nina Shah, Parameswaran N. Hari, Anita D'Souza
Summary: Autologous hematopoietic stem cell transplantation in multiple myeloma patients aged 75 years and above has shown excellent 2-year outcomes, but remains underutilized in this age group with significant racial and gender disparities.
Article
Oncology
Joanna Drozd-Sokolowska, Anna Waszczuk-Gajda, Przemyslaw Biecek, Katarzyna Kobylinska, Joanna Manko, Iwona Hus, Anna Szmigielska-Kaplon, Mateusz Nowicki, Joanna Romejko-Jarosinska, Magdalena Koziol, Mariola Sedzimirska, Wojciech Sachs, Krzysztof Madry, Piotr Boguradzki, Malgorzata Krol, Marek Hus, Grzegorz Basak, Jadwiga Dwilewicz-Trojaczek
Summary: Salvage autologous hematopoietic stem cell transplantation can be effective for relapsed multiple myeloma patients, especially if a sufficiently long response had been obtained to the first transplant. Important factors affecting the outcome include the quality of response, previous radiotherapy, and the time between the first and salvage transplants.
LEUKEMIA & LYMPHOMA
(2021)
Article
Immunology
Simone A. Minnie, Geoffrey R. Hill
Summary: The incidence of multiple myeloma is increasing globally, with substantial morbidity and mortality and remains largely incurable. Autologous stem cell transplantation (ASCT) has been shown to provide a progression free survival benefit in eligible patients beyond novel therapies. ASCT results in immune effects beyond cytoreduction, highlighting the potential for new immunotherapy maintenance strategies to prevent myeloma progression.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Michael Scordo, Gunjan L. Shah, Peter A. Adintori, Andrea Knezevic, Sean M. Devlin, Marissa L. Buchan, Elaina Preston, Andrew P. Lin, Natasia T. Rodriguez, Caroline A. Carino, Linh K. Nguyen, Nancy Cruz Sitner, Andrei Barasch, Mark G. Klang, Molly A. Maloy, Brooke Mastrogiacomo, Dean C. Carlow, Ryan C. Schofield, Ann E. Slingerland, John B. Slingerland, Christoph K. Stein-Thoeringer, Oscar B. Lahoud, Heather J. Landau, David J. Chung, Marcel R. M. van den Brink, Jonathan U. Peled, Sergio A. Giralt
Summary: This study investigated taste changes in patients undergoing autologous hematopoietic cell transplantation using chemical gustometry. The study found that taste testing was feasible, taste changes peaked when blood counts were lowest, and most patients recovered their taste by 100 days after transplantation. Taste changes correlated with lower food intake and higher levels of chemotherapy. Future work will focus on using personalized chemotherapy doses to reduce taste changes and matching patients' taste preferences with their diets.
Article
Multidisciplinary Sciences
Lida Zafeiri, Torbjoern akerfeldt, Andreas Tolf, Kristina Carlson, Alkistis Skalkidou, Joachim Burman
Summary: This study investigated the relationship between AMH levels and age and reproductive potential in MS patients treated with AHSCT. The results showed that although AMH concentration significantly decreased after AHSCT, six patients successfully conceived despite low concentrations, suggesting that high-dose cyclophosphamide treatment may not negatively impact fertility.
Article
Pharmacology & Pharmacy
Chengwen Teng, Christopher R. Frei
Summary: This study used the FDA Adverse Event Reporting System to examine the association between various antibiotics and delirium, finding a significant increased risk of delirium associated with multiple antibiotics.
DRUGS-REAL WORLD OUTCOMES
(2022)
Article
Pharmacology & Pharmacy
Alyssa C. Eaves, Chengwen Teng, Kirk E. Evoy, Christopher R. Frei
Summary: In this study comparing ceftaroline fosamil and daptomycin for diabetic foot infection (DFI), ceftaroline was associated with lower rates of hospital readmission and mortality within 90 days compared to daptomycin.
DRUGS-REAL WORLD OUTCOMES
(2022)
Meeting Abstract
Hematology
Kana Tai Lucero, Christopher R. Frei, Kellie J. Ryan, Obiageri O. Obodozie-Ofoegbu, Amanda M. Moore, Chengwen Teng, Xavier Jones, Zohra Nooruddin
Article
Public, Environmental & Occupational Health
Bretton Gilmore, Kelly Reveles, Christopher R. Frei
Summary: Vaping among adolescents is a growing concern that requires further research to evaluate its risks and understand the motivations behind it. This knowledge can then be used to develop effective educational and public health programs to prevent and reduce vaping among youths.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Infectious Diseases
Gaielle Harb, Teri Hopkins, Linda Yang, Kathleen Morneau, Jose Cadena-Zuluaga, Elizabeth Walter, Christopher Frei
Summary: This study evaluates the effect of MRSA nasal PCR testing on MRSA-targeted antibiotic use and clinical outcomes in patients with diabetic foot infection (DFI). The results showed a significant decrease in the duration of MRSA-targeted antibiotic use after protocol implementation. This suggests that MRSA nasal PCR testing can be used to reduce the use of MRSA-targeted antibiotics in DFI.
BMC INFECTIOUS DISEASES
(2023)
Article
Oncology
Amanda M. Moore, Zohra Nooruddin, Kelly R. Reveles, Jim M. Koeller, Jennifer M. Whitehead, Kathleen Franklin, Paromita Datta, Munaf Alkadimi, Lance Brannman, Ion Cotarla, Andrew J. Frankart, Tiernan Mulrooney, Xavier Jones, Christopher R. Frei
Summary: Black patients in the US shoulder a disproportionate burden of lung cancer but are underrepresented in important immunotherapy trials. This study evaluates the relationship between race and the clinical use of durvalumab, an immunotherapy for non-small cell lung cancer. The study finds that race did not impact treatment patterns in patients with unresectable stage III NSCLC treated with durvalumab at the VHA.
Article
Oncology
Cassandra Walker, Amy Horowitz, Zohra Nooruddin, Christopher R. Frei
Summary: This retrospective study evaluated the incidence of invasive fungal infections (IFIs) in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib. The incidence of IFIs was found to be 1.3%, with common fungal infections including Cryptococcus, Aspergillus, and Pneumocystis. Further research is needed to examine the relationship between ibrutinib and IFI incidence, as well as to identify clinical risk factors for IFIs.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Article
Cardiac & Cardiovascular Systems
Sarah Stahlman, Stephanie Huizar-Garcia, Justina Lipscomb, Christopher Frei, Ashley Oliver
Summary: This study examined the impact of an educational class on heart failure (HF) patients and their caregivers. The results showed that the class decreased worsening HF, ED visits, and hospital admissions, and improved patient quality of life and confidence in disease management.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Medicine, Research & Experimental
Corbyn M. Gilmore, Grace C. Lee, Susanne Schmidt, Christopher R. Frei
Summary: The purpose of this study was to assess the proportion of inpatients with community-acquired bacterial pneumonia (CABP) in special populations who received guideline-concordant antibiotics. The results showed that black patients were less likely to receive guideline-concordant antibiotics, while Hispanic patients were more likely to receive them, with non-Hispanic white patients falling in between.
JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE
(2023)
Article
Medicine, General & Internal
Lauren Bjork, Teri Hopkins, Linda Yang, Chengwen Teng, Xavier Jones, Jose Cadena, Elizabeth Walter, Christopher R. Frei
Summary: This study compares the treatment failure rates of oral beta-lactams and fluoroquinolones for Enterobacterales bloodstream infections. The results show that the failure rates are comparable between the two groups. This study suggests that beta-lactams may be as effective as fluoroquinolones for the treatment of Enterobacterales BSI without the associated risks.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2023)
Article
Medicine, Research & Experimental
Christopher R. R. Frei, Yong-Hee P. Chun, Linda M. M. McManus, Julie Barker, Amanda M. M. Moore
Summary: Research education and training in Translational Science plays a crucial role in developing a competent workforce and advancing studies to improve human health. An evaluation of a Translational Science Training (TST) TL1 Program showed that participants had significantly better research output and impact compared to nonparticipants. Furthermore, the program was found to be equally effective for female and male participants, as well as those from underrepresented backgrounds.
JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE
(2022)
Meeting Abstract
Oncology
Amanda Moore, Zohra Nooruddin, Kelly R. Reveles, Paromita Datta, Lance Brannman, Ion Cotarla, Andrew Frankart, Tiernan Mulrooney, Xavier Jones, Christopher R. Frei
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Paromita Datta, Amanda Moore, Christopher R. Frei, Kelly R. Reveles, Lance Brannman, Ion Cotarla, Andrew Frankart, Tiernan Mulrooney, Munaf Alkadimi, Jennifer Whitehead, Kathleen Franklin, Renee Reichelderfer, Madison H. Williams, Ryan A. Williams, Sarah Allison Smith, Xavier Jones, Zohra Nooruddin
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Munaf Alkadimi, Amanda Moore, Christopher R. Frei, Kelly R. Reveles, Lance Brannman, Ion Cotarla, Andrew Frankart, Tiernan Mulrooney, Paromita Datta, Jennifer Whitehead, Kathleen Franklin, Renee Reichelderfer, Madison H. Williams, Ryan A. Williams, Sarah Allison Smith, Xavier Jones, Zohra Nooruddin
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
A. Moore, Z. Nooruddin, K. R. Reveles, P. Datta, L. Brannman, I. Cotarla, A. Frankart, T. Mulrooney, X. Jones, C. R. Frei
JOURNAL OF THORACIC ONCOLOGY
(2022)
